Beijing Hezerprui Biotechnology

HezePrui Biotechnology is a clinical-stage Chinese biopharmaceutical company focused on the discovery and development of innovative antibody therapeutics for autoimmune and inflammatory diseases. The company leverages its proprietary technology platforms to develop a robust pipeline of monoclonal and bispecific antibodies targeting validated pathways such as IL-17, BAFF/APRIL, and IL-4R. Its lead programs are currently in mid-stage clinical trials, aiming to provide more effective treatment options for conditions like psoriasis and systemic lupus erythematosus. HezePrui is headquartered in Beijing and maintains a strong focus on R&D and clinical translation within the immunology space.